Long-Term Drug Survival of TNF Inhibitor Therapy in RA Patients: A Systematic Review of European National Drug Registers
Table 2
Pooled drug survival rates with number of patients/studies evaluated for ETA, ADA, and INF at different time points among the included studies (12 comparative studies evidence).
Biologic pretreatment status
Intervention
6 m
12 m
18 m
24 m
36 m
48 m
60 m
Biologic-naive studies
ADA
83.9 (1556)
74.4 (1339)
67.7 (1339)
63.6 (1339)
57.6 (1339)
47.2 (1093)
47.5 (769)
ETN
84.5 (1280)
82.1 (1064)
74.6 (1064)
71.5 (1064)
64.6 (1048)
58.5 (1117)
52.2 (517)
INF
82.2 (2027)
69.0 (1924)
60.7 (1924)
55.8 (1924)
47.0 (1804)
42.4 (1503)
37.1 (1134)
Overall comparative evidence
ADA
87.0 (3194)
76.2 (3278)
70.8 (2538)
63.4 (3278)
53.1 (3278)
47.2 (1093)
47.5 (769)
ETN
88.1 (3333)
80.1 (3062)
75.1 (2470)
67.6 (3062)
57.2 (3046)
51.0 (1636)
52.2 (517)
INF
84.3 (3356
70.9 (3318)
64.1 (2881)
55.6 (3318)
42.9 (3198)
39.0 (1865)
37.1 (1134)
ADA: adalimumab; ETN: etanercept; INF: infliximab; represents the number of studies involved.